United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Roivant's $7.1B Telavant sale to Roche demonstrated potential, but the company's stock has underperformed. Read my analysis ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

I am once again making MannKind Corp. (MNKD) my "Top Pick" for more aggressive investors in 2025, advises Nate Pile, editor of Nate’s Notes.

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension (PAH) drug, Winrevair (sotatercept), for a more advanced version of the ...